Equity Overview
Price & Market Data
Price: $5.81
Daily Change: -$0.238 / 4.09%
Daily Range: $5.80 - $6.20
Market Cap: $43,858,624
Daily Volume: 207,544
Performance Metrics
1 Week: -5.31%
1 Month: 6.51%
3 Months: 74.26%
6 Months: 51.03%
1 Year: 39.24%
YTD: 35.71%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.